Silver Book Fact

Use of an epidermal growth factor inhibitor in the treatment of metastatic colon cancer patients without the KRAS gene mutation saw survival rates of 15.6 months, compared to 5.6 months in those without the mutation.

Lievre A, Bachet J, Boige V, Cayre A, et al. KRAS Mutations as an Independent Prognostic Factor in Patients with Advanced Colorectal Cancer Treated with Cetuximab. J Clin Oncol. 2008; 26(3): 374-9. http://www.ncbi.nlm.nih.gov/pubmed/18202412

Reference

Title
KRAS Mutations as an Independent Prognostic Factor in Patients with Advanced Colorectal Cancer Treated with Cetuximab
Publication
J Clin Oncol
Publication Date
2008
Authors
Lievre A, Bachet J, Boige V, Cayre A, et al.
Volume & Issue
Volume 26, Issue 3
Pages
374-9
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Human Value

Related Facts

  • The 5-year survival rate for all cancers diagnosed from 1996-2003 is 66%, up from 50% in 1975-1977. This improvement reflects progress in early diagnosis and improvements in treatment.  
  • Investments in cancer research and development between 1998 and 2000 has generated 23 million additional healthy years of life and $1.9 trillion of additional social value.  
  • Between August 2004 and July 2014, the FDA approved: Six new anticancer therapeutics Five new uses for previously approved anticancer therapeutics Two new uses for imaging agents One new use for a screening test  
  • The standard treatment for prostate cancer used to require radical prostatectomy. Now, less invasive therapies like brachytherapy have been shown to have equal outcomes with fewer side effects.  
  • Surgical biopsy for lumps in the breast was found by one study to cost 2 1/2 to 3 times more than image-guided core-needle biopsy ($698 versus $243).